New R&D Protocol at Wyeth Could Enable Firm to Rely More on Biomarkers, Other PGx Components | GenomeWeb
Wyeth in June launched an internal R&D protocol that it said will rely more on biomarker and other pharmacogenomic data to improve its drug-discovery and -development programs.
The new system, which Wyeth calls Learn and Confirm, will result in broad management changes, alter the way the firm populates clinical trials, and modify how its R&D teams interact. In the end the protocol may result in more pharmacogenomic-based therapies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.